Is wGRS Associated With DD Recurrence?

Is the Weighted Genetic Risk Score Associated With Dupuytren Disease Recurrence?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02983162

Enrollment

427

Registered

2016-12-06

Start date

2017-03-10

Completion date

2018-08-01

Last updated

2022-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dupuytren Contracture

Brief summary

Rationale: Retrospectively reviewing the participants of the GODDAF database, revealed a significant association between the weighted genetic risk score and Dupuytren disease recurrence. However, a significant dose-response relation was not found. This might be caused by underestimating the recurrence rate, due to the retrospective nature of determining recurrence. Therefore, we want to do a follow-up measurement of the GODDAF participants, to see whether they suffered from recurrent disease. Objective: We aim to determine whether the wGRS is associated with recurrent DD. Study design: An observational study, in which the participants of the GODDAF study are followed up. Study population: Patients affected by Dupuytren disease, aged 18-96 years, who were previously included in another study on the genetic basis of Dupuytren disease. Intervention (if applicable): NA Main study parameters/endpoints: The main study parameter is the presence of recurrent Dupuytren disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* DD patient * participant in the GODDAF study * genetic data passed the quality control * surgical treatment of DD * written informed consent

Exclusion criteria

* Decisionally incapacitated * Patients treated for DD with collagenase or radiotherapy

Design outcomes

Primary

Measure	Time frame	Description
Presence of recurrent Dupuytren disease	1 day	there is only one measurement in this study

Secondary

Measure	Time frame	Description
Severity of Dupuytren recurrence	1 day	there is only one measurement in this study

Countries

Netherlands

Outcome results